Biolytx Pharmaceuticals is an emerging drug development company based in Oklahoma City, Oklahoma, dedicated to addressing the crisis of antibiotic drug resistance. Specializing in the advancement of antimicrobial peptide drug candidates, Biolytx focuses on treating serious pathogens that currently lack effective therapeutic options.
With a core technology centered around developing novel antibiotic peptides for combating hospital-acquired infections, including those resistant to existing antibiotics, Biolytx aims to progress its pipeline to facilitate collaborations with pharmaceutical companies for clinical trials. Led by CEO Doug Branch, the company's innovative approach targets drug-resistant bacteria, offering potential solutions to critical healthcare challenges.
Generated from the website